4,544 Shares in Illumina, Inc. $ILMN Purchased by Pure Financial Advisors LLC

Key Points

• Pure Financial Advisors LLC purchased 4,544 shares of Illumina, Inc. during the second quarter, valued at approximately $434,000.
• Illumina's stock price recently opened at $102.12, showing a 2.8% increase, with a market cap of $15.70 billion.
• Analysts have mixed ratings for Illumina, with an average target price of $123.33, indicating a cautious outlook amid varied buy and hold ratings from multiple brokerages.

Pure Financial Advisors LLC purchased a new position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 4,544 shares of the life sciences company's stock, valued at approximately $434,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ILMN. Rise Advisors LLC lifted its stake in Illumina by 173.6% during the first quarter. Rise Advisors LLC now owns 353 shares of the life sciences company's stock worth $28,000 after purchasing an additional 224 shares during the period. Rakuten Securities Inc. lifted its stake in Illumina by 290.3% during the first quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company's stock worth $29,000 after purchasing an additional 270 shares during the period. Center for Financial Planning Inc. bought a new position in Illumina during the first quarter worth about $33,000. PFS Partners LLC lifted its stake in Illumina by 400.0% during the first quarter. PFS Partners LLC now owns 500 shares of the life sciences company's stock worth $40,000 after purchasing an additional 400 shares during the period. Finally, Golden State Wealth Management LLC lifted its stake in Illumina by 123.2% during the first quarter. Golden State Wealth Management LLC now owns 529 shares of the life sciences company's stock worth $42,000 after purchasing an additional 292 shares during the period. Institutional investors own 89.42% of the company's stock.

Illumina Stock Up 2.8%

NASDAQ:ILMN opened at $102.12 on Friday. The stock's fifty day moving average price is $99.07 and its two-hundred day moving average price is $89.85. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $156.66. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.41 and a current ratio of 1.81. The company has a market cap of $15.70 billion, a price-to-earnings ratio of 12.93, a P/E/G ratio of 2.40 and a beta of 1.40.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.17. The firm had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.12 billion. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The business's revenue for the quarter was down 4.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.36 EPS. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. On average, analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have commented on ILMN. Robert W. Baird raised their price target on shares of Illumina from $84.00 to $105.00 and gave the stock a "neutral" rating in a research note on Monday, July 28th. Canaccord Genuity Group lifted their target price on shares of Illumina from $99.00 to $105.00 and gave the company a "hold" rating in a research note on Friday, August 1st. Weiss Ratings reiterated a "sell (d+)" rating on shares of Illumina in a research note on Saturday, September 27th. Daiwa Capital Markets cut shares of Illumina from an "outperform" rating to a "neutral" rating and set a $94.00 target price for the company. in a research note on Tuesday, August 12th. Finally, Evercore ISI lifted their target price on shares of Illumina from $116.00 to $128.00 and gave the company an "outperform" rating in a research note on Tuesday, July 8th. Six research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Illumina has an average rating of "Hold" and an average target price of $123.33.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.